精神益生菌市場－全球產業規模、佔有率、趨勢、機會和預測：促效劑、劑型、應用、分銷管道、區域和競爭格局，2021-2031年

全球益生菌市場預計將從 2025 年的 1.4301 億美元成長到 2031 年的 1.7367 億美元，複合年成長率為 3.29%。

益生菌是指活的微生物，當攝取足夠量時，它們能夠作用於腸腦軸，從而對個體的心理健康產生有益影響。推動這一市場成長的關鍵因素包括消費者對消化系統健康與心理健康之間密切聯繫的認知不斷加深，以及焦慮和壓力等心理問題的日益增加。此外，越來越多的科學研究證實了這些特定微生物療法的有效性，這也加速了市場成長，因為越來越多的人尋求天然、非藥物的方法來改善認知功能和情緒。

然而，該行業面臨著許多挑戰，包括複雜的法律規範以及需要統一的臨床檢驗來支持特定的健康相關聲明，這可能會減緩產品開發和消費者接受度。雖然產業協會提供的2025年精神益生菌產業的具體數據很少，但包括精神益生菌在內的整個益生菌補充劑產業需求強勁。根據國際益生菌協會的數據，2023年全球益生菌補充劑市場規模達90億美元。

市場促進因素

全球精神健康障礙盛行率的不斷上升是推動全球益生菌市場發展的主要動力。憂鬱症、焦慮和壓力等問題的普遍增加，使得人們迫切需要創新且有效的治療方法。隨著醫療系統和個人積極尋求預防和支持心理健康的策略，益生菌作為一種有前景的選擇正日益受到關注。這個問題的規模十分巨大。根據健康指標與評估研究所 (IHME) 預測，到 2023 年，全球將有 15% 的人口患有精神疾病，這一驚人的數據正在推動相關研究的資金投入，並鼓勵公眾接受天然的心理健康療法。

隨著腸腦軸研究的不斷進展和檢驗，市場成長正在加速。不懈的科學探索正在揭示連接中樞神經系統和腸道菌群的複雜雙向通訊網路，為益生菌的研發奠定了堅實的科學基礎。這種日益深入的理解正在刺激新產品的研發，並增強人們對益生菌健康益處的認知。為了支持這一趨勢，美國國家環境健康科學研究所 (NIEHS) 於 2025 年 7 月在 Grants.gov 網站上發布的一項資助機會公告顯示，計劃津貼400 萬美元用於研究腸道菌群與大腦之間的聯繫。這筆資金將推動對這些產品的功效和作用機制進行更深入的研究。精神健康問題帶來的巨大經濟負擔進一步凸顯了這個市場的需求。根據聯合國新聞 2025 年引用世界衛生組織 (WHO) 數據的報告，焦慮和憂鬱症每年對全球經濟造成約 1 兆美元的損失。

市場挑戰

全球益生菌市場面臨的主要障礙之一是複雜的法規環境以及對統一臨床證據的嚴格要求，這些證據對於支持特定健康益處至關重要。這些監管壁壘減緩了新產品的研發和上市速度。監管法規分散且地區差異顯著，導致益生菌產品在健康益處的分類、標籤和評估方法方面缺乏一致性。這種全球一致性的缺失迫使製造商調整產品以滿足不同的國家標準，從而增加了研發成本並延長了產品上市時間。

此外，對檢驗特定心理健康益處的嚴格臨床證據要求直接阻礙了市場成長。對新型益生菌菌株（尤其是那些旨在產生複雜心理效應的菌株）進行必要的黃金標準人體試驗，會給企業帶來巨大的營運和財務負擔。缺乏監管機構核准的、具有明確科學依據的功效聲明，使得醫療專業人員和消費者都持謹慎態度，限制了其廣泛的市場滲透。國際益生菌協會歐洲分會於2025年8月發布的報告強調了這個問題的嚴重性。報告指出，歐洲食品安全局（EFSA）僅核准了355項益生菌健康聲明中的一項。這清楚地表明，獲得監管部門核准極其困難，並對行業創新和產品推廣產生了負面影響。

市場趨勢

塑造全球益生菌市場的關鍵趨勢之一是向客製化益生菌產品的快速轉型。這項策略著重於根據個體獨特的腸道菌群、遺傳背景和特定的心理健康需求來客製化微生物療法。這種精準的標靶療法摒棄了「一刀切」的做法，旨在提高焦慮和壓力等問題的治療效果。在這一轉變過程中，先進的診斷工具發揮著至關重要的作用，透過深入了解個別腸-腦軸的動態變化，增強了消費者的信心，並為高階產品的開發鋪平了道路。為了彰顯這項持續的科學支持，Biocodex 微生物組基金會於 2026 年 4 月宣布了一項 5 萬美元的研究津貼，重點研究「利用腸道菌群：對健康、疾病、診斷和治療的影響」。

另一個重要的市場趨勢是益生菌、人工智慧 (AI) 和數位健康技術的融合。這種融合正在為消費者互動和新產品開發創造新的機會。機器學習和人工智慧正成為進行詳細微生物組評估的關鍵，有助於識別對心理健康有益的特定益生菌菌株並最佳化產品配方。此外，數位平台透過實現腸道健康遠端監測、提供個人化提案和提高治療依從性，正在提升使用者體驗並擴大市場覆蓋範圍。這些技術的融合正在建立以數據為中心的網路，有望徹底改變益生菌的研究、處方和使用方式。這項變革的驅動力來自 Google.org 於 2026 年 1 月啟動的 2,000 萬美元「AI for Science Fund」（人工智慧科學基金），該基金旨在推進先進的科學人工智慧應用，包括微生物組的基礎模型。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球益生菌市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依類型分類的精神藥物（鏈球菌、雙叉桿菌、乳酸桿菌、梭菌等）
  • 劑型（粉劑、液體/流劑、片劑、其他）
  • 依目的（壓力管理、情緒健康/情緒改善、憂鬱症、焦慮症、睡眠障礙、其他）
  • 銷售管道細分（超級市場和大賣場、專賣店、線上、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美益生菌市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲精神益生菌市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區益生菌市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲精神益生菌市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲精神益生菌市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球精神益生菌市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• InnovixLabs
• Bened Biomedical Co., Ltd
• Nutrimmun GmbH
• Kerry Group Plc.
• Sabinsa Corporation
• Lallemand Health Solutions Inc.
• DuPont de Nemours, Inc.
• Uplift Food Pty Ltd.
• Nature's Bounty Co. Ltd.
• BioGaia Group

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Psychobiotics Market is projected to grow from USD 143.01 Million in 2025 to USD 173.67 Million by 2031 at a 3.29% CAGR. Psychobiotics comprise live microorganisms that provide mental health advantages to individuals by influencing the gut-brain connection when consumed in sufficient quantities. The primary catalysts for this market's growth include a heightened consumer understanding of the strong relationship between digestive health and mental wellness, coupled with the escalating rates of psychological issues like anxiety and stress. Additionally, the increasing body of scientific research validating the effectiveness of these specific microbial treatments accelerates market growth, as individuals increasingly look for natural, non-medication-based options to enhance their cognitive function and mood.

Nevertheless, the industry encounters significant hurdles due to intricate regulatory frameworks and the necessity for uniform clinical verification to back up specific health-related claims, potentially slowing down both product creation and consumer adoption. Although precise figures for the psychobiotics sector from industry groups are scarce for 2025, the wider probiotic supplements industry, which includes psychobiotics, shows robust engagement. Data from the International Probiotics Association indicates that the worldwide market for probiotic supplements reached a valuation of USD 9.0 billion in 2023.

Market Driver

The rising worldwide prevalence of mental health conditions acts as a major catalyst for the global psychobiotics market. The widespread increase in issues like depression, anxiety, and stress has generated a pressing need for innovative and successful treatment methods. Psychobiotics are standing out as an encouraging option as both medical systems and individuals actively pursue preventative and supplemental strategies for mental wellness. The magnitude of this issue is immense; the Institute for Health Metrics and Evaluation reported that 15% of the global population suffered from mental disorders in 2023, a staggering statistic that fuels financial backing for research and encourages the public to embrace natural mental health remedies.

Market growth is further accelerated by ongoing progress and validation in gut-brain axis studies. Continuous scientific explorations are shedding light on the complex, two-way communication networks linking the central nervous system with the gut microbiome, establishing a solid scientific base for psychobiotics. This growing comprehension encourages the creation of new products and reinforces the validity of health claims associated with psychobiotics. Highlighting this trend, a July 2025 Notice of Funding Opportunity from the National Institute of Environmental Health Sciences (NIEHS) on Grants.gov revealed a prospective $4,000,000 award for investigating the gut microbiome-brain connection, a financial injection that drives deeper study into product effectiveness and mechanisms. The massive economic toll of mental health problems further highlights the necessity of this market, as UN News reported in 2025, referencing the World Health Organization, that anxiety and depression exact an estimated annual cost of US$1 trillion on the global economy.

Market Challenge

A major obstacle facing the Global Psychobiotics Market is the intersection of complicated regulatory environments and the strict requirement for uniform clinical proof to support distinct health claims. Such regulatory barriers slow down the creation of new products and their introduction into the market. Because regulations are divided and vary widely across different regions, there is a lack of consistency in how psychobiotic items are classified, labeled, and evaluated for health claims. This absence of global alignment forces producers to modify their offerings to meet diverse national standards, thereby elevating the expenses associated with development and prolonging the time it takes to launch a product.

Additionally, market growth is directly hindered by the demanding need for solid clinical evidence to verify specific mental health advantages. Undertaking the essential, gold-standard human trials for new psychobiotic strains-particularly those aimed at intricate psychological effects-imposes substantial operational and financial strains on businesses. In the absence of definitive, scientifically backed claims endorsed by regulatory bodies, both medical professionals and consumers maintain a cautious stance, which in turn limits wider market penetration. The severity of this issue is highlighted by an August 2025 report for the International Probiotic Association Europe, which noted that the EFSA approved just one out of 355 evaluated probiotic health claims, demonstrating the intense difficulty of securing regulatory backing and its subsequent negative effect on industry innovation and product embrace.

Market Trends

A leading trend shaping the Global Psychobiotics Market is the rapid movement toward customized psychobiotic products. This strategy focuses on customizing microbial treatments to align with a person's unique gut microbiome, genetic background, and distinct mental health requirements. By stepping away from one-size-fits-all approaches, this targeted precision seeks to improve the effectiveness of treatments for issues such as anxiety and stress. Enhanced diagnostic tools play a vital role in this shift, building consumer confidence and paving the way for high-end products through a profound comprehension of individual gut-brain axis dynamics. Underscoring this continuous scientific backing, the Biocodex Microbiota Foundation declared a $50,000 USD research grant in April 2026 focused on "Harnessing the Gut Microbiome: Impacts on Health, Disease, Diagnosis and Therapeutics."

Another major trend in the market is the merging of psychobiotics with artificial intelligence and digital health technologies. This blend provides fresh opportunities for both interacting with consumers and developing new products. Machine learning and AI are becoming essential for in-depth microbiome evaluations, helping to pinpoint exact psychobiotic strains that offer mental health perks and to perfect product compositions. Furthermore, digital platforms enhance the user journey and broaden the market's scope by enabling remote monitoring of gut health, offering tailored suggestions, and boosting treatment compliance. These combined technologies are establishing data-centric networks that are set to transform how psychobiotics are researched, prescribed, and used, a shift supported by Google.org's January 2026 introduction of a $20 million AI for Science Fund aimed at advancing advanced scientific AI applications, including foundational models for the microbiome.

Key Market Players

• InnovixLabs
• Bened Biomedical Co., Ltd
• Nutrimmun GmbH
• Kerry Group Plc.
• Sabinsa Corporation
• Lallemand Health Solutions Inc.
• DuPont de Nemours, Inc.
• Uplift Food Pty Ltd.
• Nature's Bounty Co. Ltd.
• BioGaia Group

Report Scope

In this report, the Global Psychobiotics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psychobiotics Market, By Psychotropic Agent

• Streptococcus
• Bifidobacterium
• Lactobacillus
• Clostridium
• Others

Psychobiotics Market, By Form

• Powder
• Liquid/Fluid
• Tablets
• Others

Psychobiotics Market, By Application

• Stress Management
• Mood Health & Mood Upliftment
• Depression
• Anxiety
• Sleep Problems
• Others

Psychobiotics Market, By Distribution Channel

• Supermarkets and Hypermarkets
• Specialty Stores
• Online
• Others

Psychobiotics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psychobiotics Market.

Available Customizations:

Global Psychobiotics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Psychobiotics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
  • 5.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
  • 5.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
  • 5.2.4. By Distribution Channel (Supermarkets and Hypermarkets, Specialty Stores, Online, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Psychobiotics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Psychotropic Agent
  • 6.2.2. By Form
  • 6.2.3. By Application
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Psychobiotics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Psychotropic Agent
      • 6.3.1.2.2. By Form
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Psychobiotics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Psychotropic Agent
      • 6.3.2.2.2. By Form
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Psychobiotics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Psychotropic Agent
      • 6.3.3.2.2. By Form
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Distribution Channel

7. Europe Psychobiotics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Psychotropic Agent
  • 7.2.2. By Form
  • 7.2.3. By Application
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Psychobiotics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Psychotropic Agent
      • 7.3.1.2.2. By Form
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Psychobiotics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Psychotropic Agent
      • 7.3.2.2.2. By Form
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Psychobiotics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Psychotropic Agent
      • 7.3.3.2.2. By Form
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Psychobiotics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Psychotropic Agent
      • 7.3.4.2.2. By Form
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Psychobiotics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Psychotropic Agent
      • 7.3.5.2.2. By Form
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Psychobiotics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Psychotropic Agent
  • 8.2.2. By Form
  • 8.2.3. By Application
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Psychobiotics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Psychotropic Agent
      • 8.3.1.2.2. By Form
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Psychobiotics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Psychotropic Agent
      • 8.3.2.2.2. By Form
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Psychobiotics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Psychotropic Agent
      • 8.3.3.2.2. By Form
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Psychobiotics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Psychotropic Agent
      • 8.3.4.2.2. By Form
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Psychobiotics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Psychotropic Agent
      • 8.3.5.2.2. By Form
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Psychobiotics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Psychotropic Agent
  • 9.2.2. By Form
  • 9.2.3. By Application
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Psychobiotics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Psychotropic Agent
      • 9.3.1.2.2. By Form
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Psychobiotics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Psychotropic Agent
      • 9.3.2.2.2. By Form
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Psychobiotics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Psychotropic Agent
      • 9.3.3.2.2. By Form
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Distribution Channel

10. South America Psychobiotics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Psychotropic Agent
  • 10.2.2. By Form
  • 10.2.3. By Application
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Psychobiotics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Psychotropic Agent
      • 10.3.1.2.2. By Form
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Psychobiotics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Psychotropic Agent
      • 10.3.2.2.2. By Form
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Psychobiotics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Psychotropic Agent
      • 10.3.3.2.2. By Form
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Psychobiotics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. InnovixLabs
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bened Biomedical Co., Ltd
• 15.3. Nutrimmun GmbH
• 15.4. Kerry Group Plc.
• 15.5. Sabinsa Corporation
• 15.6. Lallemand Health Solutions Inc.
• 15.7. DuPont de Nemours, Inc.
• 15.8. Uplift Food Pty Ltd.
• 15.9. Nature's Bounty Co. Ltd.
• 15.10. BioGaia Group

16. Strategic Recommendations

17. About Us & Disclaimer